‘It shouldn't be expensive to be healthy.' Introducing smoodi DIY-smoothie systems
Advertisement
Founder Pascal Kriesche (a Boston-based Harvard grad and father of two), is passionate and persuasively eloquent about his venture to make the company's product accessible and to empower healthy habits. 'Our entire team is mission-driven,' he says. 'It shouldn't be expensive to be healthy, and this can help build healthy habits. We want you to see what you consume, and food waste is minimal. We're so excited to multiply this and make it sustainable.'
Get Winter Soup Club
A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter.
Enter Email
Sign Up
Smoodi stations are available nationwide through 23 different distributors. Local outlets include Boston University City Convenience, Simmons College, The Quin, MCPHS University, and In Town Market, among others, and the company's goal is to make its product available everywhere from gas stations in the middle of nowhere to waiting rooms in hospitals and airports.
Advertisement
Karen Campbell can be reached at
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Implantable Remote Patient Monitoring Devices Market to Grow 21.7% CAGR by 2029
"Innovation-Driven and Knowledge-Intensive: Implantable Remote Patient Monitoring Devices Seek Flexible, Integrated Solutions Amid Accelerating Market Timelines and Rising Competition" Boston, June 12, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the 'Global Implantable Remote Patient Monitoring Devices Market' is expected to grow from $7.6 billion in 2024 to $20.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 21.7% from 2024 to 2029. The report on the implantable remote patient monitoring (IRPM) device market analyzes market shares by product, indication and end users. It segments the market into device types, such as cardiovascular, brain, gastrointestinal, hematological, respiratory, and musculoskeletal monitoring devices. Indication consists of cardiovascular diseases, brain disorders, and diabetes End users include hospitals, clinics, and home healthcare settings. Additionally, it offers a study of the competitive landscape, regional analysis, consumer insights, and a supply chain analysis, helping stakeholders make informed decisions and identify strategic opportunities. This report is particularly relevant today because implantable remote patient monitoring (IRPM) devices are transforming healthcare by enhancing patient outcomes, lowering healthcare costs, and increasing accessibility. These devices facilitate continuous monitoring of chronic conditions, enabling real-time data collection and analysis, which can lead to early detection of complications and more timely interventions. The factors driving the market's growth include: Chronic Diseases and the Aging Population: The rise in chronic diseases and the global aging population increase the need for continuous health monitoring. Implantable devices help manage these conditions more effectively, reducing hospital visits and improving patient outcomes. Demand for mHealth Applications: mHealth apps are gaining in popularity for their convenience and real-time health data. They enhance implantable devices by providing comprehensive health data, driven by the widespread use of smartphones and rising awareness of the benefits of digital health. Improved Wireless Technologies: Advances in wireless tech, such as 5G, improve the reliability and efficiency of remote patient monitoring. These technologies enable faster data transmission and more stable connections, which are crucial for real-time health monitoring. Request a sample copy of the global market for implantable remote patient monitoring (IRPM) devices report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $6.5 billion Market size forecast $20.3 billion Growth rate CAGR of 21.7% from 2024 to 2029 Segments covered By product, disease indication, end user, and region Regions covered North America, Europe, Asia-Pacific, and the Rest of World (RoW) Market drivers Increasing prevalence of chronic diseases due to an aging population. Growing demand for mHealth applications. Improved wireless communication technologies. Interesting facts: Reducing Hospital Readmissions: Implantable RPM devices can decrease hospital readmissions by up to 30%, which is crucial for managing chronic conditions like heart failure. Innovative Power Sources and AI Integration: Some implantable devices are powered by the human body, eliminating the need for external batteries. Additionally, integrating artificial intelligence (AI) enhances their predictive capabilities, allowing real-time adjustments to patient care. The report addresses the following questions: What is the projected size and growth rate of the global market for implantable remote patient monitoring devices? The global market for implantable remote patient monitoring devices was valued at $6.5 billion in 2023 and is expected to reach $20.3 billion by the end of 2029, at a CAGR of 21.7% from 2024 to 2029. What are the key factors driving the growth of the market? These include the increasing prevalence of chronic diseases due to an aging population, growing demand for mHealth applications, and improved wireless communication technologies. What market segments does the report cover? The global market for implantable remote patient monitoring devices is segmented by product, indication, end user and region. Which indication segment will enjoy market dominance through the forecast period? The cardiovascular diseases segment will have that position. Which region has the largest share of the global market for implantable remote patient monitoring devices? North America holds the largest share of the market. Leading Companies Include: ABBOTT AVERTIX MEDICAL INC. BIOTRONIK BOSTON SCIENTIFIC CORP. CARDIAC RMS DEXCOM INC. EBR SYSTEMS INC. ENDOTRONIX INC. INJECTSENSE INC. IMPULSE DYNAMICS MEDICO S.R.L. MEDTRONIC PROFUSA INC. QURA LLC. VITALCONNECT Navigate Uncertainty with ConfidenceIn times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we are here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape, giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That is why, for a limited time, we are offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Purchase a copy of the report directly from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. CONTACT: BCC Research Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 hours ago
- Business Wire
Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line
LOS ANGELES--(BUSINESS WIRE)-- Tombot, the robotics company that earned widespread acclaim at CES earlier this year for its lifelike robotic puppy, Jennie, announced today the successful close—and oversubscription—of its $6.1 million Series A funding round. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD) and other health issues. 'Tombot is entering a high-demand, underserved market at the intersection of mental health and assistive technology,' said Tombot CEO and Co-Founder Tom Stevens. 'Over 300 million seniors around the world with dementia and mild cognitive impairment are unable to care for a live animal at a time when they need the companionship of a pet more than ever. Millions of other individuals suffering from mental health adversities are in a similar predicament.' With artistic design by Jim Henson's Creature Shop, and developed with the guidance of clinical experts, patients, and their families, Jennie provides many of the health benefits associated with live animal ownership, such as reduced stress and loneliness. Jennie will be used in private homes, assisted living and memory care communities, and other settings where live animals are not always safe or practical. Covered with sensors to respond to touch, voice commands, movement, and other sensory inputs, Jennie is rechargeable, fully cleanable, and comes with an optional caregiver app to customize behaviors and ease the burden of caregiving. With participation from both new and existing investors, the funding round was led by Caduceus Capital Partners, a Nashville-based team of veteran healthcare investors with a primary emphasis on accelerating growth of early-stage digital health startups. 'We identified the growing need for robotic companions several years ago and believe the market is now on the brink of exponential expansion,' said Dave Vreeland, senior managing partner, Caduceus Capital Partners. 'By 2030, the U.S. is projected to have 73 million seniors – an aging population that will increasingly face challenges related to loneliness, companionship, and chronic disease management. These issues are rapidly surpassing the capacity of human caregivers alone. Tombot is uniquely positioned to lead this emerging sector and drive widespread adoption of robotic companions." 'This investment will be rocket fuel for Tombot,' said Stevens. 'We are most appreciative of our company's Board of Directors for their ongoing guidance, and are especially grateful to Caduceus for recognizing and supporting Tombot's mission of creating robotic animals that transform the daily lives of individuals, families, and communities facing health adversities.' According to Stevens, this milestone investment will be used to expand Tombot's team, finalize engineering, complete regulatory and safety certifications, and prepare its first robotic pet for customer shipments to its more than 16,000 pre-order and waitlist customers. About Tombot Tombot, Inc., established in 2017, designs realistic robotic companion animals for individuals unable to safely or practically care for a live animal. After Tom Stevens' own mother's progressive dementia necessitated the rehoming of her beloved pet dog for safety reasons, Tom launched Tombot. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD). The Tombot founding team built a prior startup into one of the world's largest legal automation companies and was successfully acquired.
Yahoo
4 hours ago
- Yahoo
Over 44,000 Pounds Of Shrimp Have Been Recalled Due To Listeria
Open any freezer and there's a good chance that you'll find a bag of frozen shrimp. This type of shellfish is delicious in so many dishes, from pasta to salads to tacos. But if you recently purchased a bag of frozen shrimp, you're going to want to check it before cooking. Bornstein Seafoods Inc., a Bellingham, Washington-based company, has recalled 44,550 pounds of shrimp due to possible listeria monocytogenes contamination, according to the FDA. The company says the listeria was found during a routine sampling, but no illnesses have been reported. On June 10, the company announced the recall of Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat in 1 and 5-pound bags. According to the recall, the product was distributed to both retailers and wholesale distributors in Oregon, California, Washington, and British Columbia of Canada. But it's worth noting that the products could have been distributed beyond these states and provinces. Listeria is a bacteria that can cause listeriosis, which can cause mild to severe symptoms. According to the FDA, mild cases can include symptoms like fever, nausea, vomiting, and diarrhea, while more severe cases can be life-threatening, especially for at-risk groups: those with weakened immune systems, adults over 65, pregnant people, and newborns. To find out if you have recalled shrimp, you'll need to check the UPC codes and lot numbers, which can be found on the bag. A list of affected product can be found here. If you do have recalled product, consumers are urged to return it to the place of purchase for a refund and to direct any questions to Andrew Bornstein at Andrew@ You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails
